摘要
急性肺损伤(acute lung injury,ALI)是临床常见的危重症,其严重阶段即为急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS),死亡率高达30%~50%,严重威胁人们生命健康。即使患者幸存,肺功能被严重损害,生活质量亦被严重影响,给患者、家庭及社会造成较大的经济负担。ALI的病理机制复杂,其有效治疗是医学界一大难题。目前对ALI的治疗策略主要包括呼吸支持治疗、药物治疗、基因治疗、细胞移植等。本文就ALI的治疗研究进展进行简要综述。
Acute lung injury(ALI)is a common clinical critical illness.Its exacerbation stage is acute respiratory distress syndrome(ARDS).The mortality rate is as high as 30%-50%,which seriously threatens people’s life and health.Even if the patients survive,the function of lung is severely impaired,thus severely affecting the quality of the patients’life and causing a large economic burden on the patient,family and society.The complex pathological mechanisms of ALI make its effective treatment still a tremendous challenge clinically.Presently,the treatment strategies of ALI mainly include respiratory support therapy,drug therapy,gene therapy,cell transplantation and other means.A brief review of the research progress of ALI therapy is presented.
作者
沈陶冶
郭剑浩
王小娟
姜赛平
SHEN Taoye;GUO Jianhao;WANG Xiaojuan;JIANG Saiping(Department of Clinical Pharmacy,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2021年第3期366-370,共5页
Chinese Journal of Modern Applied Pharmacy
基金
浙江省医药卫生科技计划项目(2017KY345)
浙江省基础公益研究计划项目(LQ20H300003)。
关键词
急性肺损伤
药物治疗
基因治疗
细胞移植
acute lung injury
drug therapy
gene therapy
cell transplantation
作者简介
沈陶冶,女,主管药师,Tel:15957161451,E-mail:32908328@qq.com;通信作者:王小娟,女,博士,主管药师,Tel:15356153197,E-mail:xiaojuanwang1992@zju.edu.cn;通信作者:姜赛平,男,博士,主任药师,Tel:13857196312,E-mail:j5145@zju.edu.cn。
